anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sodium Bicarbonate Injection, USP is a sterile, nonpyrogenic, hypertonic solution of sodium bicarbonate (NaHCO3) in water for injection for administration by the intravenous route as an electrolyte replenisher and systemic alkalizer.

Solution is offered in concentrations of 8.4%. See table in HOW SUPPLIED section for contents and characteristics.

The solution contains no bacteriostat, antimicrobial agent or added buffer and are intended only for use as a single-dose injection, the approximate pH of the solutions is 8. When smaller doses are required, the unused portion should be discarded.

Sodium bicarbonate, 84 mg is equal to one milliequivalent each of Na+ and HCO3-. Sodium Bicarbonate, USP is chemically designated NaHCO3, a white crystalline powder soluble in water.

Water for Injection, USP is chemically designated H2O.
BACKGROUND: Partner notification and treatment for sexually transmitted infections are critical to prevent reinfection and reduce transmission. However, partner treatment rates are low globally. Expedited partner therapy (EPT), in which the patient delivers treatment directly to their partner, may result in more partners treated. We assessed partner notification and treatment outcomes among pregnant women in Gaborone, Botswana, including EPT intent, uptake, and effectiveness.
METHODS: The Maduo study was a cluster-controlled trial evaluating the effect of antenatal Chlamydia trachomatis and Neisseria gonorrhoeae infection screening in pregnant women. The intervention arm received screening at first antenatal care (ANC), third-trimester, and postnatal care visits. The standard-of-care arm received screening postnatally. Participants screening positive were given options for partner treatment: contact slips, in-clinic treatment, or EPT. Self-reported partner notification and treatment outcomes were assessed at test-of-cure visit.
RESULTS: Of 51 women who screened positive for C. trachomatis / N. gonorrhoeae at first ANC and returned for test of cure, 100% reported notifying their partner and 48 (94.1%) reported their partner received treatment. At third trimester 100% (n = 5), reported partners were treated. Before testing, EPT intent was lower than EPT uptake at all time points (first ANC: 17.9% vs. 80.4%; third-trimester: 57.1% vs. 71.4%; postnatal care: 0% vs. 80.0%). Partner treatment success was 100% among EPT users compared with 70% among nonusers ( P = 0.006).
CONCLUSIONS: Partner notification and treatment success was high in this population. Despite low pretest intent to use EPT, uptake was high and associated with greater partner treatment success. Our findings suggest that EPT may be a successful partner treatment strategy to pursue in low- and middle-income countries.
Conventional care consists of specialist assessment in conjunction with pre-operative surgical visits and patient education. Patients in the conventional care group are provided with pre- and postoperative information face-to-face by paper-based method. Patients will be admitted and mobilised on the day of the surgery, and discharged one to three days after surgery. The follow-up visit, conducted by a physiotherapist, is conducted after 6 to 8 weeks post-discharge for patients with TKA and after 8 to 12 weeks for patients with THA.
Participants receive 1.25 mg/kg enfortumab vedotin intravenously (IV) over 30 minutes on days 1 and 8 of cycles 1-5 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 5 cycles of enfortumab vedotin and up to 17 cycles of pembrolizumab in the absence of disease progression or unacceptable toxicity. Beginning on cycle 1 day 1, participants also undergo standard of care intensity modulated radiation therapy (IMRT) once daily (QD) for 32 days over 6.5-8 weeks. Participants also undergo TURBT, cystoscopy, as well as imaging throughout the study.
Problem drinking gay and bisexual men who try to quit drinking are at risk for relapse to heavy or problematic drinking because their social lives and social outlets are often strongly associated with alcohol. These men are most receptive to interventions focused on moderation of drinking rather than abstinence. However moderation-oriented cognitive-behavior therapy (CBT) and naltrexone (NTX) are both well established treatments for problem drinkers who wish to moderate, rather than stop, drinking. Research suggests that combining these treatments may enhance their efficacy.

This study combines moderation-oriented CBT with NTX in the treatment of problem drinking gay and bisexual men, who do not wish to abstain from alcohol, to evaluate their efficacy alone and in combination. We also propose to utilize new data collection technology, Interactive Voice Response, to collect data on daily relations among drinking, sexual behavior and psychological variables thought to mediate treatment response. Our objectives are to evaluate the efficacy of 12 weeks of randomly assigned treatment, with 100 mg of NTX or placebo, combined with brief supportive therapy or modified, behavioral self-control therapy specifically tailored to gay/bisexual men; to evaluate conditional relationships between heavy drinking and likelihood of HIV risk behavior; and to evaluate daily associations among mood, craving, self-efficacy, motivation, and drinking. Assessments will include baseline, 3, 6, \& 9 month follow-up. A substudy of the treatment trial will be conducted to collect and bank samples from blood for research aimed at associating naturally occurring differences in DNA with patient response to NTX, and with potential mediational mechanisms of action of NTX. Information gathered on genes or gene products may be used in conjunction with data on clinical and psychological factors obtained as part of the clinical trial to evaluate relationships among genetic variants, drug effects, and mechanisms of treatment response. Patients will be asked to give a blood sample at Week 0 of the clinical trial for the purpose of carrying out genetic research.
Participants assigned to the experimental condition are asked to view the modules within the app for 8 weeks. The mobile app contains content based on cognitive behavioral therapy for insomnia (CBT-I) enhanced with content from brief alcohol interventions.
NEW MATERIAL:A plasma factor strengthening a fibrinogenolysis activity to induce a thromboplastinogen effect. USE:A fibrinolytic agent. PREPARATION:For example, human plasma is mixed with solid ammonium sulfate to give a 30% saturated and the resultant precipitates are collected by a centrifugal separation method. The collected precipitates are dissolved in a buffer solution and the prepared solution is applied to a heparin-sepharose column. Protein adsorbed in the column is eluted with a buffer solution containing sodium chloride in a linear concentration gradient, and an active fraction is applied to a zinc-chelate sepharose column and an adsorbed substrate is eluted with a buffer solution containing EDTA. The elute is applied to a aprotinin-sepharose column and eluted with a 6M urea solution, etc. The elute is further applied to a protein A-sepharose column and eluted with a buffer solution having a pH of 3.0 to provide a plasma factor exhibiting a man band of a mol.wt. of 80kD on a SDS-PAGE and strengthening the fibrinogenolysis with heparin.
The invention relates to the technical field of meal replacement compositions, and particularly relates to a weight-losing meal replacement composition and a preparation method thereof. Aiming at the problem that the weight-losing meal replacement powder in the prior art has unsatisfactory weight-losing effect and blood fat-reducing effect. The meal replacement composition provided by the invention comprises 10-30 parts of angelica keiskei; 10-40 parts of malt; 10-30 parts of kudzu roots; 5-15 parts of coix seeds; 20-30 parts of soybean. The invention also provides a preparation method of the meal replacement composition and application of the meal replacement composition in preparation of health-care products or medicines with the function of regulating blood fat. The compound meal replacement composition provided by the invention has an excellent weight-losing effect and can obviously reduce blood fat. And the weight-losing effect and the blood fat-reducing effect of the health-care food are superior to those of the condition that any one component in the formula is used independently.
PURPOSE: To explore the influence of postoperative Hirschsprung-associated enterocolitis (post-HAEC) on long-term outcomes and to identify risk factors of post-HAEC.
METHODS: The medical records of 304 eligible patients diagnosed with Hirschsprung's disease (HSCR) were reviewed. We analyzed the clinical characteristics of post-HAEC and its influence on long-term outcomes. Furthermore, risk factors for early and recurrent HAEC were identified separately.
RESULTS: The overall incidence of post-HAEC was 29.9% (91/304). We categorized early HAEC as occurring within postoperative 3 months (n = 39) and recurrent HAEC as occurring ≥ 3 episodes within postoperative 6 months (n = 25). Patients with early HAEC were more likely to experience worse nutritional status, defecation function, and quality of life compared to those with late or no episodes (P < 0.05). Similarly, the adverse influences of recurrent HAEC on these outcomes were also significant (P < 0.05). The risk factors for early HAEC included preoperative undernutrition, long-segment HSCR, and postoperative Grade 3-4 complications within 30 days. For recurrent HAEC, risk factors were preoperative malnutrition, non-parental caregivers, long-segment HSCR, and postoperative Grade 3-4 complications within 30 days.
CONCLUSION: Classification of post-HAEC based on the first episode time and frequency was necessary. The earlier or more frequent episodes of post-HAEC have detrimental influences on long-term outcomes. Furthermore, risk factors for early and recurrent HAEC were different.
1,069,110. Intra-uterine appliances. DESERET PHARMACEUTICAL CO. Inc. April 26, 1966 [June 4, 1965; Oct. 24, 1965], No. 18184/66. Heading A5R. An intra-uterine contraceptive device of polyethylene material is formed with two flexible loops 14, 15, each loop having one end portion which is inturned and free, and a second end portion forming part of a tail part 13. As shown, the tail part 13 extends within an inserter tube 1 from which it may be ejected into the uterus with an inserter rod 5. The tail part is formed with nodes 9, Fig. 2 (not shown) by which it is secured to the inserter rod, the tail part being severed from the inserter rod with forceps after the device has been fitted, so that a node remains protruding from the cervix as an indication that the device is correctly positioned. The inserter rod 5 and the inserter tube 1 are provided with indicator marks 17, 3 to assist in ejecting and positioning the device. In inserting the device into the uterus, it is wholly contained within the tube 1 with the flexible loops temporarily straightened out. A gelatin cap Fig. 17 (not shown) may be fitted over the end of the tube to assist insertion. In embodiments, the tail part 13 is connected to the inserter rod 5 by a string (Figs. 19, 26, 27, not shown), or by two strings connected to each other by a bead (Figs. 28, 29, not shown). The tail part 13 may be shaped to provide two further loops (Figs. 28 or 30, not shown) and the loop 15 may be formed at its free end (Figures 31-34, not shown) with a member to provide a cap to the inserter tube within which the device is fitted. The device may be of X-ray-opaque material and the device and the inserter apparatus may be provided sterilized in a sealed transparent envelope.
The invention is intended for treatment and prophylaxy of infectious diseases and others in which urine from a sick person contains antigens or gaptens from the incitant of the disease (for reception autourine vaccine or urine vaccine). It is also exposed to necessary processing as well as for treatment of the diseases in accordance with presence of agressive antibodies (diabetes and others), and malignant new formations. Urine from a sick person, containing antigens from the incitant of the disease, cleaned from urates and subjected to necessary processing results in killing (inactive) and live weakened vaccine which can be successfully used as an inoculative of the material for prophylaxy of this disease. Also, it is offered to use the processed urine from children and teenagers, at the point when there are the most contents of hormones in the organism. This includes growing hormones, sexual hormones and others needed for achievement of the effect of the rejuvenation of the recipient. The processed urine is entered into the recipients organism with parenteral injections.
For external use only. Avoid contact with eyes, lips, broken or inflamed skin and all mucous membranes. Mild burning or stinging may occur. Peeling of the skin may increase as the salicylic acid works to loosen excess keratin. If excessive burning, stinging or peeling occurs, discontinue use and consult your physician. If swallowed, get medical help or contact Poison Control Center right away. KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.
How Supplied

  * LUMOXITI (moxetumomab pasudotox-tdfk) for injection is supplied as a sterile, preservative-free, white to off-white lyophilized cake or powder in a 1 mg single-dose vial. Each carton (NDC 73380-4700-1) contains one single-dose vial.
  * IV Solution Stabilizer is supplied as a sterile, preservative-free, colorless to slightly yellow, clear solution free from visible particles in a 1 mL single-dose vial. The IV Solution Stabilizer is packaged separately from LUMOXITI. Each carton (NDC 73380-4715-9) contains one single-dose vial. Do not use the IV Solution Stabilizer to reconstitute LUMOXITI.



Only one vial of IV Solution Stabilizer should be used per administration of LUMOXITI.

Storage and Handling

Refrigerate LUMOXITI and IV Solution Stabilizer at 2°C to 8°C (36°F to 46°F), in original carton to protect from light. Do not freeze. Do not shake.
In Part 1, participants will receive single oral doses of MK-6552 in ascending fashion approximately 6 hours apart for a single day, based on safety and tolerability of the previous dose. In Part 2, participants will receive multiple days of MK-6552 dosing (7 consecutive days) at the highest safe and well tolerated MK-6552 dose determined on an individual basis from Part 1.
ABSTRACT: Trauma-induced coagulopathy (TIC) is a global inflammatory state accompanied by coagulation derangements, acidemia, and hypothermia, which occurs after traumatic injury. It occurs in approximately 25% of severely injured patients, and its incidence is directly related to injury severity. The mechanism of TIC is multifaceted; proposed contributing factors include dysregulation of activated protein C, increased tPA, systemic endothelial activation, decreased fibrinogen, clotting factor consumption, and platelet dysfunction. Effects of TIC include systemic inflammation, coagulation derangements, acidemia, and hypothermia. Trauma-induced coagulopathy may be diagnosed by conventional coagulation tests including platelet count, Clauss assay, international normalized ratio, thrombin time, prothrombin time, and activated partial thromboplastin time; viscoelastic hemostatic assays such as thrombelastography and rotational thrombelastography; or a clinical scoring system known as the Trauma Induced Coagulopathy Clinical Score. Preventing TIC begins in the prehospital phase with early hemorrhage control, blood product resuscitation, and tranexamic acid therapy. Early administration of prothrombin complex concentrate is also being studied in the prehospital environment. The mainstays of TIC treatment include hemorrhage control, blood and component transfusions, and correction of abnormalities such as hypocalcemia, acidosis, and hypothermia.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
The application belongs to the technical field of medicines, and discloses a new application of sorafenib, in particular to an application of sorafenib in preparing a medicine for treating myeloproliferative tumors. The myeloproliferative tumor is polycythemia vera or the myeloproliferative tumor with drug resistance of luccotinib. The sorafenib used for treating the polycythemia vera provides a new treatment approach for patients with polycythemia vera and provides more choices for clinicians and patients. For patients with drug-resistant marrow proliferative tumors of lucentitinib, sorafenib can provide continued oral drug therapy for the patients, and is free from receiving bone marrow transplantation. Sorafenib can be chemically synthesized, and the cost is lower than that of a biological agent. And has been approved by FDA and NMPA for clinical treatment. The side effects are less and light, the tolerance of clinical patients is good, and the burden of the patients is light.
Use with caution in patients with impaired gag reflex, unconscious, or semiconscious patients, and patients prone to regurgitation or aspiration. Observe these patients during administration of GoLYTELY, especially if it is administered via nasogastric tube.Use with caution in patients with impaired gag reflex, unconscious, or semiconscious patients, and patients prone to regurgitation or aspiration. Observe these patients during administration of GoLYTELY, especially if it is administered via nasogastric tube.

Do not combine GoLYTELY with starch-based thickeners [see Dosage and Administration ( 2.1)] . Polyethylene glycol (PEG), a component of GoLYTELY, when mixed with starch- thickened liquids reduces the viscosity of the starch-thickened liquid. When a PEG-based product used for another indication was mixed in starch-based pre-thickened liquids used in patients with dysphagia, thinning of the liquid occurred and cases of choking and potential aspiration were reported.
Verified infection with SARS-CoV-2 during wave 1 and 2 (i.e. wild type or alfa variants), prior to 2021-02-28. Fully recovered within 12 weeks of primary infection. No other diagnoses.
BACKGROUND: Radical inguinal lymph node dissection (rILND) is the most available treatment to cure penile cancer (PC) with limited inguinal-confined disease. However, guidelines regarding acceptable boundaries of rILND are controversial, and consensus is lacking. The authors aimed to standardize the surgical boundaries of rILND with definite pathological evidence and explore the distribution pattern of inguinal lymph nodes (ILNs) in PC.
METHODS: A total of 414 PC patients from two centers who underwent rILND were enrolled. The ILN distribution was divided into seven zones anatomically for pathological examination. Student's t test and Kaplan-Meier survival analysis were used.
RESULTS: ILNs displayed a funnel-shaped distribution with high density in superior regions. ILNs and metastatic nodes are present anywhere within the radical boundaries. Positive ILNs were mainly concentrated in zone I (51.7%) and zone II (41.3%), but there were 8.7% and 12.3% in inferior zones V and VI, respectively, and 7.1% in the deep ILNs. More importantly, a single positive ILN and first-station positive zone was detected in all seven regions. Single positive ILNs were located in zones I through VI in 40.4%, 23.6%, 6.7%, 18.0%, 4.5%, and 1.1%, respectively, and 5.6% presented deep ILN metastasis directly.
CONCLUSIONS: The authors established a detailed ILN distribution map and displayed lymphatic drainage patterns with definite pathological evidence using a large cohort of PC patients. Single positive ILNs and first-station metastatic zones were observed in any region, even directly with deep ILN metastasis. Only rILND can ensure tumor-free resection without the omission of positive nodes.
Sodium nitrite, one of the active ingredients in NITHIODOTE has the chemical name nitrous acid sodium salt. The chemical formula is NaNO2 and the molecular weight is 69.0. Sodium thiosulfate, the second active ingredient in NITHIODOTE has the chemical name thiosulfuric acid, disodium salt, pentahydrate. The chemical formula is Na2S2O3∙ 5H2O and the molecular weight is 248.17. The structural formulae are:

Structure of Sodium Nitrite

Structure of Sodium Thiosulfate Pentahydrate

NITHIODOTE is a cyanide antidote which contains one 10 mL glass vial of a 3% solution of sodium nitrite injection and one 50 mL glass vial containing a 25% solution of sodium thiosulfate injection.

Sodium nitrite injection is a sterile aqueous solution and is intended for intravenous injection. Each vial contains 300 mg of sodium nitrite in 10 mL solution (30 mg/mL). Sodium nitrite injection is a clear solution with a pH between 7.0 and 9.0.

Sodium thiosulfate injection is a sterile aqueous solution and is intended for intravenous injection. Each vial contains 12.5 grams of sodium thiosulfate in 50 mL solution (250 mg/mL). Each mL also contains 2.8 mg boric acid and 4.4 mg of potassium chloride. The pH of the solution is adjusted with boric acid and/or sodium hydroxide. Sodium thiosulfate injection is a clear solution with a pH between 7.5 and 9.0.
This study is a prospective, observational, medical chart review for at least six standards of care visits up to 1 year after subject consents for study participation. There will be a retrospective chart review for patients who underwent endoscopic suturing procedures from October 2014 - April 2019. Those subjects will undergo no additional tests and procedures as part of this study. All data will be collected from patient's electronic health records (EHR) of the hospital In addition; a prospective chart review will be performed for patients who will undergo endoscopic suturing procedures from April 2019 to April 2021. All the subjects enrolled in prospective chart review will be first consented for their study participation. Subjects will undergo a clinically indicated endoscopic suturing procedure and standard of care follow up visits.
This will be a 12-week, randomized, controlled study with 90 subjects. At enrollment, subjects will be randomized to the Active Treatment or Sham Treatment. All subjects will receive dietary supplements (calcium and vitamin D) for the duration of the study. Subjects will be asked to self-administer daily at-home treatments with the device at least 5 times each week. The investigators will evaluate safety via adverse events reported to the research staff and via responses to a survey on potential side effects. DXA scans will be obtained at the Screening Visit and Visit 3 (Study Completion). Blood and urine will be collected at Day 0 (Visit 1), Week 6 (Visit 2), and Week 12 (Visit 3).
The invention discloses a preparation method of a high-molecular-based pH-sensitive medicament micelle. Phosphatidylcholine is subjected to an atom transfer radical polymerization reaction to obtain poly phosphatidylcholine. Benzyl glutamate carboxylic acid anhydride is subjected to a ring-opening polymerization reaction to obtain poly(benzyl glutamate) ester. The poly(benzyl glutamate) ester is grafted to doxorubicin through a hydrazone bond. The poly phosphatidylcholine is bonded to the poly(benzyl glutamate) ester in a manner of click chemistry to obtain a block copolymer. The block copolymer is respectively dissolved in tetrahydrofuran to obtain a solution. The solution is transferred to a dialysis bag for carrying out a dialysis process through pure water to obtain a dialysate which is filtered through a filter membrane. A freeze drying process is carried out to the filtered solution to obtain a medicant carrier micelle. The drug carrier micelle has a core-shell double-layer structure with an external layer being hydrophilic poly phosphatidylcholine and an internal layer being medicament molecule wrapping layer. The drug carrier micelle has advantages of belonging to nano particles and enabling a targeting transmission of a drug to cancer cells and a pH-sensitive releasing process in the cancer cells to be achieved. The drug carrier micelle is large in drug carrying capacity and good in stability. A targeting function of the drug carrier micelle can effectively reduce toxic and side effects of drugs on normal tissues and organs.